- $17.22m
- $9.52m
- $0.40m
Annual cashflow statement for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -23.2 | -50.3 | -65 | -24.9 | -18.4 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.89 | 6.31 | 22.8 | 8.59 | 1.82 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.2 | 3.24 | 10.8 | -3.17 | 0.479 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.1 | -37.5 | -30.4 | -18.6 | -15.3 |
| Capital Expenditures | -5.16 | -11.6 | -6.43 | -0.21 | -0.016 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -21.3 | 6.5 | 13.4 | 1.12 | 0.758 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -26.5 | -5.13 | 7.01 | 0.906 | 0.742 |
| Financing Cash Flow Items | 0.836 | -0.372 | -0.061 | 0.109 | 5.95 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 78.8 | -6.13 | 2.3 | 24.5 | 8.93 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.3 | -48.7 | -21.1 | 6.85 | -5.63 |